Your browser doesn't support javascript.
loading
Proton beam therapy for hepatocellular carcinoma with bile duct invasion.
Iizumi, Takashi; Okumura, Toshiyuki; Hasegawa, Naoyuki; Ishige, Kazunori; Fukuda, Kuniaki; Seo, Emiko; Makishima, Hirokazu; Niitsu, Hikaru; Takahashi, Mizuki; Sekino, Yuta; Takahashi, Hiroaki; Takizawa, Daichi; Oshiro, Yoshiko; Baba, Keiichiro; Murakami, Motohiro; Saito, Takashi; Numajiri, Haruko; Mizumoto, Masashi; Nakai, Kei; Sakurai, Hideyuki.
Afiliación
  • Iizumi T; Department of Radiation Oncology and Proton Medical Research Center, University of Tsukuba, 2-1-1 Amakubo, Tsukuba, 305-8576, Ibaraki, Japan. iizumi@pmrc.tsukuba.ac.jp.
  • Okumura T; Department of Radiation Oncology and Proton Medical Research Center, University of Tsukuba, 2-1-1 Amakubo, Tsukuba, 305-8576, Ibaraki, Japan.
  • Hasegawa N; Department of Gastroenterology, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan.
  • Ishige K; Department of Gastroenterology, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan.
  • Fukuda K; Department of Gastroenterology, Kasumigaura Medical Center, Ibaraki, Japan.
  • Seo E; Department of Gastroenterology, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan.
  • Makishima H; Department of Gastroenterology, Kasumigaura Medical Center, Ibaraki, Japan.
  • Niitsu H; Department of Gastroenterology, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan.
  • Takahashi M; Department of Radiation Oncology and Proton Medical Research Center, University of Tsukuba, 2-1-1 Amakubo, Tsukuba, 305-8576, Ibaraki, Japan.
  • Sekino Y; Department of Radiation Oncology and Proton Medical Research Center, University of Tsukuba, 2-1-1 Amakubo, Tsukuba, 305-8576, Ibaraki, Japan.
  • Takahashi H; Department of Radiation Oncology and Proton Medical Research Center, University of Tsukuba, 2-1-1 Amakubo, Tsukuba, 305-8576, Ibaraki, Japan.
  • Takizawa D; Department of Radiation Oncology and Proton Medical Research Center, University of Tsukuba, 2-1-1 Amakubo, Tsukuba, 305-8576, Ibaraki, Japan.
  • Oshiro Y; Department of Radiology, Mayo Clinic, Rochester, USA.
  • Baba K; Department of Radiation Oncology, Hitachi General Hospital, Tsukuba, Japan.
  • Murakami M; Department of Radiation Oncology and Proton Medical Research Center, University of Tsukuba, 2-1-1 Amakubo, Tsukuba, 305-8576, Ibaraki, Japan.
  • Saito T; Department of Radiation Oncology, Tsukuba Medical Center Hospital, Tsukuba, Japan.
  • Numajiri H; Department of Radiation Oncology and Proton Medical Research Center, University of Tsukuba, 2-1-1 Amakubo, Tsukuba, 305-8576, Ibaraki, Japan.
  • Mizumoto M; Department of Radiation Oncology and Proton Medical Research Center, University of Tsukuba, 2-1-1 Amakubo, Tsukuba, 305-8576, Ibaraki, Japan.
  • Nakai K; Department of Radiation Oncology and Proton Medical Research Center, University of Tsukuba, 2-1-1 Amakubo, Tsukuba, 305-8576, Ibaraki, Japan.
  • Sakurai H; Department of Radiation Oncology and Proton Medical Research Center, University of Tsukuba, 2-1-1 Amakubo, Tsukuba, 305-8576, Ibaraki, Japan.
BMC Gastroenterol ; 23(1): 267, 2023 Aug 03.
Article en En | MEDLINE | ID: mdl-37537527
AIM: Hepatocellular carcinoma (HCC) with bile duct invasion (BDI) (BDIHCC) has a poor prognosis. Moreover, due to the paucity of reports, there is no consensus regarding optimal management of this clinical condition yet. The aim of this study was to clarify the efficacy and safety of proton beam therapy (PBT) for BDIHCC. METHODS: Between 2009 and 2018, 15 patients with BDIHCC underwent PBT at our institution. The overall survival (OS), local control (LC), and progression-free survival (PFS) curves were constructed using the Kaplan-Meier method. Toxicities were assessed using the Common Terminology Criteria of Adverse Events version 4.0. RESULTS: The median follow-up time was 23.4 months (range, 7.9-54.3). The median age was 71 years (range, 58-90 years). Many patients were Child A (n = 8, 53.3%) and most had solitary tumors (n = 11, 73.3%). Additionally, most patients had central type BDI (n = 11, 73%). The median tumor size was 4.0 cm (range, 1.5-8.0 cm). The 1-, 2-, and 3-year OS rates were 80.0%, 58.7% and 40.2%, respectively, and the corresponding LC and PFS rates were 93.3%, 93.3%, and 74.7% and 72.7%, 9.7%, and 0.0%, respectively. Acute grade 1/2 dermatitis (n = 7, 46.7%), and grades 2 (n = 1, 6.7%) and 3 (n = 1, 6.7%) cholangitis were observed. Late toxicities such as grade 3 gastric hemorrhage and pleural effusion were observed. No toxicities of grade 4 or higher were observed. CONCLUSIONS: PBT was feasible with tolerable toxicities for the treatment of BDIHCC.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Carcinoma Hepatocelular / Terapia de Protones / Neoplasias Hepáticas Tipo de estudio: Prognostic_studies Límite: Aged / Aged80 / Humans / Middle aged Idioma: En Revista: BMC Gastroenterol Asunto de la revista: GASTROENTEROLOGIA Año: 2023 Tipo del documento: Article País de afiliación: Japón Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Carcinoma Hepatocelular / Terapia de Protones / Neoplasias Hepáticas Tipo de estudio: Prognostic_studies Límite: Aged / Aged80 / Humans / Middle aged Idioma: En Revista: BMC Gastroenterol Asunto de la revista: GASTROENTEROLOGIA Año: 2023 Tipo del documento: Article País de afiliación: Japón Pais de publicación: Reino Unido